Molecular Markers In Forecasting The Clinical Efficacy Of Infliximab In Psoriasis Patients


Biosamples (skin tissue samples taken from affection foci and blood serum) from 22 patients suffering from severe to medium psoriasis (8 women and 14 men) aged 19-57 treated with Infliximab were analyzed. As for skin tissue samples, the molecular structure of genes TNF-a, TNF-R-I and TNF-R-II, contents of cytokine TNF-a and its soluble receptors (sTNF-RI and sTNF-RII) and proteome composition was analyzed in skin tissue samples; contents of TNF-a, IL2, IL4, IL6, IL-8 and IL-10 were analyzed in the blood serum. The homozygous TT genotype of TNF-R-II gene at the 676 locus and high IL10 level in the blood serum (>2.7 pg/ml) was associated with the high intensity of the psoriasis patient response to treatment with Infliximab; the homozygous GG genotype of TNF-R-II gene at the 676 locus and low level of IL10 in the blood serum (<1.0 pg/ml) was associated with a weak response or no response to treatment with Infliximab. These results laid the basis for developing a method to forecast the treatment efficacy in psoriasis patients based on a genetically engineered biological drug - Infliximab.
Pilot results indicating a possible mutual relation between the composition of the skin proteome and psoriasis patient's therapeutic response to treatment with Infliximab have been obtained.


  1. Гинтер Е.А. Эволюция представлений о генетической природе мультифакториальных заболеваний. // Медицинская генетика. 2003. Т. 2. № 4. С. 146-156.
  2. Campalani E., Barker J. The clinical genetics of psoriasis. // Current Genomics. 2005. V. 6. P. 51-60.
  3. Скрипкин Ю.К., Мордовцев В.Н. Кожные и венерические болезни: Руководство для врачей. - М: Медицина, 1999. С. 116-118.
  4. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. // Ann. Rheum. Dis. 2004. Jul. N. 63(7). P. 755-8.
  5. Zhang M., Tracey K.J. Tumor necrosis factor. In: Thompson A.W. // In: The cytokine handbook, 3rd ed. New York. Academic press. 1998. 515-548.
  6. Cordiali-Fei P., Trento E., 'Agosto G.D. et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in sera and skin lesions. // Ann N Y Sci. 2007. Sep. Vol. 1110. P. 578-589.
  7. Saraceno R., Schipani C., Mazzota A. et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. // Pharmacol Res. 2008. Apr. Vol. 57, № 4. P. 290-295.
  8. Cordoro K.M., Feldman S.R. TNF-a Inhibitors in Dermatology. // Skin Therapy Lett. 2007. Sep. № 12(7). P. 4-6.
  9. Nash P.T., Florin T.H.J. Tumour necrosis factor inhibitors. // MJA. 2005. № 183(4). P. 205-208.
  10. Nikas S.N., Voulgari P.V., Takalou I.P. et al. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immuno-suppressive drugs, after infliximab treatment. // Ann. Rheum. Dis. 2005. Nov. № 64(11). P. 1665-7.
  11. Kalow W., Tang B.K., Endrenyi L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. // Pharmacogenetics. 1998. № 8. P. 283-289.
  12. Evans W.E., McLeod H.L. Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects. // NEJM. 2003. Feb. № 6. P. 538-549.
  13. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. // Dermatologica. 1978. № 157. P. 238-44.
  14. Bio-Rad Laboratories. Bio-Plex Human Cytokine, Chemokine, and Growth Factor Assays. Bulletin 5828.
  15. J. C. Caruso, N. Cliff, Empirical Size, Coverage, and Power of Confidence Intervals for Spearman's Rho//, Ed. and Psy. Meas. 57 (1997) pp. P. 637-654.
  16. Goodman L.A., Kruskal W.H. Measures of association for cross-classifications. // Journal of the American Statistical Association 49. 1954. P. 732-764.
  17. Reich K., Mössner R., König al. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. // J Invest Dermatol. 2002. Jan. Vol. 118, № 1. P. 155-163.
  18. Nedoszytko B., Szczerkowska-Dobosz A., Zablotna al. Association of promoter region polymorphisms in the tumor necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern polish population. // Br J Dermatol. 2007. Jul. Vol. 157, № 1. P. 165-167.
  19. Kaluza W., Reuss E., Grossmann al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. //J Invest Dermatol. 2000. Jun. Vol. 114, № 6. P. 1180-1183.
  20. Mascheretti S., Hampe J., Kühbacher al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. // Pharmacogenomics J. 2002. Vol. 2, № 2. P. 127-136.
  21. Fabris M., Di Poi E., Sacco al. TNF-alpha gene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-alpha agents: preliminary results. // Reumatismo. 2002. Vol. 54, № 1. P. 19-26.
  22. Shetty A., Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn's disease. // Am J Pharmacogenomics. 2002. Vol. 2, № 4. P. 215-221.
  23. Matsukura H., Ikeda S., Yoshimura al. Genetic polymorphisms of TNF receptor superfamily 1A and 1B (TNFRSF1A and TNFRSF1B) affect responses to infliximab in Crohn's disease patients in Japan. // Aloment Pharmacol Ther. 2008. May. № 27(9). P. 765-770.
  24. Heidenreich R., Röcken M., Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. // Int J Exp Pathol. 2009. Vol. 90, № 3. P. 232-48.
  25. Asadullah K., Sterry W., Stephanek al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. //J Clin Invest. 1998. Vol. 101, № 4. P. 783-794.
  26. Baran W., Szepietowski J.C., Mazur G. et al. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. // Acta Derm Venereol. 2008. Vol. 88, № 2. P. 113-116.
  27. Rashmi R., Rao K.S.J., Basavaraj K.H. A comprehensive review of biomarkers in psoriasis. // Clinical and Experimental Dermatology. 2009. № 34. P. 658-663.
  28. Goldstein A.M. Changing paradigms in dermatology: proteomics: a new approach to skin disease. // Clin Dermatol. 2003. Vol. 21, № 5. P. 370-374.
  29. Semprini S., Capon F., Tacconelli A. Evidence for differential S100 gene over - expression in psoriatic patients from genetically heterogeneous pedigrees. // Hum. Genetics. 2002. V. 111. P. 310-313.
  30. Broome A.M., Ryan D., Eckert R.L. S100 protein subcellular localization during epidermal differentiation and psoriasis. // J His-tochem Cytochem. 2003. 51. P. 675-685.
  31. Zibert J.R., Skov L., Thyssen J.P. et al. (2009) // J. Invest. Dermatol. (epub ahead of print).
  32. Aceto A., Caccuri A.M., Sacchetta P. et al. Dissociation and unfolding of Pi-class glutathione transferase. Evidence for a monomeric inactive intermediate. // Biochem J. 1992. July. 1. 285(Pt 1). P. 241-245.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies